SCHEMBL405345

SCHEMBL405345

Cc1cc2nc(Cl)c(Cl)nc2cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
CD44 P16070 1/20 0.42
NQO2 P16083 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 3/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MPI P34949 1/20 0.36
LMNA P02545 2/20 0.36
PGK1 P00558 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18267365 0.90 NQO2 (0.50) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL31530745 0.87 ALDH1A1 (0.56) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL121241 0.87 ALDH1A1 (0.56) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL12140042 0.83 ALDH1A1 (0.43) ALDH1A1CYP1A2CD44NQO2PDE3B
SCHEMBL29558616 0.81 TDP1 (0.50) NQO2TDP1PGK1HTTMMP1
SCHEMBL405486 0.81 TDP1 (0.50) NQO2TDP1PGK1HTTMMP1
SCHEMBL24751627 0.78 PGK1 (0.66) PGK1
SCHEMBL31399930 0.76 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL404244 0.76 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3656734 0.76 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP3A4CYP2C19CD44

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
EP-1670774-A1 QUINOXALINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-21 EP disclosed
WO-2005033088-A1 QUINOXALINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-14 WO disclosed
US-20050070527-A1 For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070527-A1 For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions HRH4, HRH3, LTB4R ALDH1A1 3818/4885CYP1A2 4512/4885CYP3A4 2635/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 ALDH1A1 1909/4885CYP1A2 2609/4885CYP3A4 2376/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 ALDH1A1 1909/4885CYP1A2 2609/4885CYP3A4 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.